FibroGen Announces Clinical Data from Dose Escalation Phase 1b Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer will be Presented at the 2024 American Society of Clinical Oncology Annual Meeting
24 avr. 2024 16h02 HE | FibroGen, Inc.
SAN FRANCISCO, April 24, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that clinical data from the dose escalation portion of the Phase 1b/2 study of FG-3246 in combination...
MacroGenics Provides Phase 2 TAMARACK Study Early Interim Safety Data and Plans for Future Disclosures
03 avr. 2024 16h30 HE | MacroGenics, Inc.
Early interim safety data from Phase 2 TAMARACK study, including comparison to retrospective analysis from Phase 1 study, as submitted in ASCO abstractCompany plans to provide updated interim data,...
OBI Logo.jpg
浩鼎將在 AACR 2024 年會 發表四篇論文
18 mars 2024 05h00 HE | OBI Pharma Inc.
台灣台北電, March 18, 2024 (GLOBE NEWSWIRE) -- 台灣浩鼎生技(4174)旗下自行開發的抗TROP2抗體藥物複合體(ADC)OBI-992,臨床前數據證明,它在多種動物實驗模式均顯示高效的抗腫瘤活性、優異的藥物動力學表現,和良好的安全性,具有發展為同類最佳抗TROP2...
OBI Logo.jpg
浩鼎将在 AACR 2024 年会   发表四篇论文
18 mars 2024 05h00 HE | OBI Pharma Inc.
台湾台北电, March 18, 2024 (GLOBE NEWSWIRE) -- 台湾浩鼎生技(4174)旗下自行开发的抗TROP2抗体药物复合体(ADC)OBI-992,临床前数据证明,它在多种动物实验模式均显示高效的抗 肿瘤活性、优异的药物动力学表现,和良好的安全性,具有发展为同类最佳抗TROP2 ADC的潜力。...
OBI Logo.jpg
OBI Pharma Announces Poster Presentations at the AACR 2024 Annual Meeting for OBI-992 and GlycOBI™ ADC platform
18 mars 2024 05h00 HE | OBI Pharma Inc.
TAIPEI, Taiwan, March 18, 2024 (GLOBE NEWSWIRE) -- OBI Pharma, Inc. (TPEx: 4174) today announced preclinical data for OBI-992, a potential best-in-class anti-TROP2 Antibody-Drug Conjugate (ADC)....
MacroGenics Provides Update on Corporate Progress and 2023 Financial Results
07 mars 2024 16h01 HE | MacroGenics, Inc.
Presentation of preliminary data from TAMARACK Phase 2 study of vobra duo in mCRPC patients expected at ASCO 2024Initiation of Phase 1 study of MGC026, MacroGenics' first topoisomerase I...
OBT-RGB_1417_544 (2).jpg
Oxford BioTherapeutics Announces Launch of Enhanced Discovery Platform, OGAP®-Verify, at World ADC Conference 2024
07 mars 2024 04h00 HE | Oxford BioTherapeutics
OGAP®-Verify allows for significantly enhanced sensitivity and specificity for improved target selection, dramatically accelerating drug target discoveryOGAP-Verify is now more sensitive than...
MacroGenics to Participate in Upcoming Investor Conferences
01 mars 2024 17h48 HE | MacroGenics, Inc.
ROCKVILLE, MD, March 01, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative monoclonal...
MacroGenics Announces Date of Fourth Quarter 2023 Financial Results Conference Call
27 févr. 2024 17h45 HE | MacroGenics, Inc.
ROCKVILLE, MD, Feb. 27, 2024 (GLOBE NEWSWIRE) --  MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative antibody-based...
Vaccinex logo
Vaccinex Announces Multiple New Agreements for Access to ActivMAb® Antigen Virus Technology
21 févr. 2024 08h00 HE | Vaccinex, Inc.
Eight new antibody discovery agreements incorporate Vaccinex’s powerful ActivMAb® Drug Discovery Platform ActivMab® platform enables the discovery and development of high value antibodies against...